Last updated: 2026-10-16 05:16:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Virax Biolabs Group Limited (VRAX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.63, with a market capitalization of $1.39M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.56 to $21.75. This page covers its latest market performance, valuation, price trends and company information.
$1.39M | |
$1.65 | |
$7,250.00 | |
$1.56 | |
$1.65 | |
14.77K | |
415.80K | |
-- | |
$21.75 | |
$1.56 | |
-- | |
-- |
Virax Biolabs Group Limited (VRAX) last closed at $1.65 as of 2026-10-15 23:31:00, unchanged from the previous close of $1.65.
During the latest regular trading session, VRAX traded between $1.56 and $7,250.00, with a volume of 14.77K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Virax Biolabs Group Limited (VRAX) moved from $2.03 to $1.63, representing a decline of 19.95% ($0.40).
The stock traded between $1.56 and $2.33 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 125.79 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.3%
VRAX is currently trading at $1.63, placing it 0.3% of the way from its 52-week low of $1.56 to its 52-week high of $21.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
| Employees | 26 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Virax Biolabs Group Limited (VRAX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.